Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma

Liao, Wanying; Long, Junyu; Li, Yiran; Xie, Fucun; Xun, Ziyu; Wang, Yanyu; Yang, Xu; Wang, Yunchao; Zhou, Kang; Sang, Xinting; Zhao, Haitao

doi:10.3389/fcell.2022.910749

Cited by 2 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AL122125.1 emerged as an independent prognostic factor, providing novel information about LUSC risk-stratification ( 63 ). Similar approach has also been applied for the analysis of bladder, colon cancers, hepatocellular carcinoma and hematological malignancies, in particular like acute myelocytic leukemia ( 28 , 64 – 73 , 77 , 78 ).…”

Section: M6a-related Lncrnas Signaturesmentioning

confidence: 99%

The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer

et al. 2023

View full text Add to dashboard Cite

Most of our transcribed RNAs are represented by non-coding sequences. Long non-coding RNAs (lncRNAs) are transcripts with no or very limited protein coding ability and a length >200nt. They can be epigenetically modified. N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), 7-methylguanosine (m7G) and 2’-O-methylation (Nm) are some of the lncRNAs epigenetic modifications. The epigenetic modifications of RNA are controlled by three classes of enzymes, each playing a role in a specific phase of the modification. These enzymes are defined as “writers”, “readers” and “erasers”. m6A and m5C are the most studied epigenetic modifications in RNA. These modifications alter the structure and properties, thus modulating the functions and interactions of lncRNAs. The aberrant expression of several lncRNAs is linked to the development of a variety of cancers and the epigenetic signatures of m6A- or m5C-related lncRNAs are increasingly recognized as potential biomarkers of prognosis, predictors of disease stage and overall survival. In the present manuscript, the most up to date literature is reviewed with the focus on m6A and m5C modifications of lncRNAs and their significance in cancer.

show abstract

Section: M6a-related Lncrnas Signaturesmentioning

confidence: 99%

The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

Non-coding RNAs as potential targets in metformin therapy for cancer

Zhang,

Wu,

Liu

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

Metformin, a widely used oral hypoglycemic drug, has emerged as a potential therapeutic agent for cancer treatment. While initially known for its role in managing diabetes, accumulating evidence suggests that metformin exhibits anticancer properties through various mechanisms. Several cellular or animal experiments have attempted to elucidate the role of non-coding RNA molecules, including microRNAs and long non-coding RNAs, in mediating the anticancer effects of metformin. The present review summarized the current understanding of the mechanisms by which non-coding RNAs modulate the response to metformin in cancer cells. The regulatory roles of non-coding RNAs, particularly miRNAs, in key cellular processes such as cell proliferation, cell death, angiogenesis, metabolism and epigenetics, and how metformin affects these processes are discussed. This review also highlights the role of lncRNAs in cancer types such as lung adenocarcinoma, breast cancer, and renal cancer, and points out the need for further exploration of the mechanisms by which metformin regulates lncRNAs. In addition, the present review explores the potential advantages of metformin-based therapies over direct delivery of ncRNAs, and this review highlights the mechanisms of non-coding RNA regulation when metformin is combined with other therapies. Overall, the present review provides insights into the molecular mechanisms underlying the anticancer effects of metformin mediated by non-coding RNAs, offering novel opportunities for the development of personalized treatment strategies in cancer patients.

show abstract

Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma

Cited by 2 publications

References 44 publications

The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer

The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer

Non-coding RNAs as potential targets in metformin therapy for cancer

Contact Info

Product

Resources

About